Get to know the approach and vaccine research that Hilleman Labs, employs to provide better health care facilities to developing countries.

1. The Science of Vaccination- an insight from Hilleman Labs
Get to know the approach and vaccine research that Hilleman Labs, employs to provide better health
care facilities to developing countries.
There is big gap between the healthcare facilities provided by the developing nations and developed
nations. Vaccination programs help developing countries, defend deadliest of diseases. Hilleman Labs, a
partner of Merck & Co. and Wellcome Trust, have channelized their vaccine research to help people
fight and overcome fatal diseases in developing countries. Vaccine manufacturing needs research, ultra-
modern techniques, and artisan. The artisans at Hilleman Labs focus on:
Diseases of importance to developing countries
Transformational technology for vaccine development and administration
The vaccines like rotavirus vaccines, human papillomavirus vaccines, TB vaccines, pneumococcal
conjugate vaccines, and Hepatitis A vaccines are developed for diseases responsible for highest
mortality and morbidity rates in developing countries. The vaccines are developed and delivered based
on disease targets and antigens, which are calculated on epidemiologic data and disease burden. The
heat stability, usability, and affordability of the vaccine are improved either by using existing technology
or inventing a new one.
The vaccine research model of Hilleman Labs encapsulates the following:
Due-Diligence
Identify Vaccine Antigen
Identify Vaccine Technology
Optimization
Preclinical Development
Clinical Phase I / II
Technology Transfer for Manufacturing
The vaccine development cycle is explained below.
The Project

2. selection process:
Public health interest (Possible reasons why this vaccine is needed)
Technical probability (What is the probability of vaccine’s success)
Financial feasibility (Cost and investment involved in vaccine manufacture and licensing)
Keeping in mid National Regulatory Authority (NRA) and WHO Guidelines
Consulting stakeholders and peer groups
“It is estimated that globally 0.6 million children under the age of 5 die annually due to rotavirus
diarrhea and another 2 million are hospitalized. 90% of these deaths occur in developing countries.” –
Courtesy: Hilleman Labs.
Public health systems that can ensure fairness in global health scenario will be a reality only through
easy and affordable access to life-saving immunization programs. Well equipped with transformational
vaccine research technologies, we will deliver new age preventive healthcare to the developing world in
the near future.
Our expertise in vaccine research is channelized towards helping people in the developing world to fight
the deadliest of diseases with vaccines that are within their reach. A first-of-its-kind initiative, Hilleman
Laboratories is an equal joint-venture partnership formed between Merck & Co., a global research-
driven pharmaceutical company and Wellcome Trust, a global charitable foundation dedicated to
human and animal health. Headquartered in India, Hilleman Laboratories is an international
organization strengthened by the presence of global leadership and scientific team, which is working
incessantly to develop safe, effective, affordable and sustainable vaccines for developing countries
Thermo stable Rotavirus vaccine is one of the current projects that Hilleman Labs, has been working on.
The research on rotavirus vaccine, examine formulations to improve stability, usability, portability and
affordability of thin strips or granules. Making vaccination a medium to combat deadly diseases helps
save lives.
We are executing high-impact programs that help accomplish vital research to catalyze vaccine science,
a step that would be immensely benefitting healthcare research in India subsequently leading to an
upsurge in the development of life saving vaccines.
“Many first-generation vaccines have not been developed with the specific needs of countries with poor
infrastructure for vaccine delivery in mind. This is a much needed exploration of how to tackle one of
the greatest public health and logistics challenges in the developing world - distributing life-saving
vaccines without the requirement for large bulk shipments, expensive warehousing and costly, difficult-
to-maintain refrigerated shipping paths from the manufacturing plant to the patient.”
Hilleman Laboratories is a vaccine manufacture and committed to developing high impact, TB vaccines,
Hepatitis A vaccines, and affordable vaccines for people in developing countries in an innovative and
sustainable manner.